SCHEMBL19239790

SCHEMBL19239790

N#Cc1ccc2c(n1)CC2

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SOS2 Q07890 1/20 0.36
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
HTR2B P41595 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.34
NQO1 P15559 1/20 0.34
KDM4E B2RXH2 2/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32
CTSK P43235 2/20 0.32
ADRA2A P08913 2/20 0.31
ADRA2B P18089 2/20 0.31
ADRA2C P18825 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2960628 0.88 SMN1; SMN2 (0.47) HTR2AHTR2CSMN1; SMN2KDM4EALDH1A1
SCHEMBL18183649 0.88 KDM4E (0.44) HTR2AHTR2CSMN1; SMN2KDM4EALDH1A1
SCHEMBL29740385 0.88 SMN1; SMN2 (0.47) HTR2AHTR2CSMN1; SMN2KDM4EALDH1A1
SCHEMBL4204764 0.83 HTR2C (0.44) HTR2AHTR2CHTR2B
SCHEMBL21818701 0.77 HTR2A (0.31) SOS2HTR2AHTR2CHTR2B
SCHEMBL12101153 0.77 PNMT (0.49) HTR2AHTR2CHTR2BSMN1; SMN2ADRA2A
SCHEMBL31133318 0.77 HTR2A (0.31) SOS2HTR2AHTR2CHTR2B
SCHEMBL3306895 0.75 MAPT (0.44) KDM4EALDH1A1LMNAMAPT
SCHEMBL25432593 0.70 TAS1R3 (0.35) SMN1; SMN2ALDH1A1MAPT
SCHEMBL31003080 0.68 MAPT (0.33) SOS2SMN1; SMN2NQO1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10865213-B2 Max binders as MYC modulators and uses thereof MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2020-12-15 US disclosed
US-20190144466-A1 MAX BINDERS AS MYC MODULATORS AND USES THEREOF MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2019-05-16 US disclosed
WO-2017143059-A1 MAX BINDERS AS MYC MODULATORS AND USES THEREOF MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2017-08-24 WO disclosed
US-20170233405-A1 MAX BINDERS AS MYC MODULATORS AND USES THEREOF MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2017-08-17 US disclosed
US-20170233405-A1 MAX BINDERS AS MYC MODULATORS AND USES THEREOF MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2017-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170233405-A1 MAX BINDERS AS MYC MODULATORS AND USES THEREOF MYC, MYCBP, MYCBP2 SOS2 2824/4885HTR2A 3947/4885HTR2C 4255/4885
US-10865213-B2 Max binders as MYC modulators and uses thereof MYC, MYCBP, MYCBP2 SOS2 2824/4885HTR2A 3947/4885HTR2C 4255/4885
US-20190144466-A1 MAX BINDERS AS MYC MODULATORS AND USES THEREOF MYC, MYCBP, MYCBP2 SOS2 2824/4885HTR2A 3947/4885HTR2C 4255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.